Letter to the USPTO Director
Policy Prescriptions to Solve the Drug Patent Problem
Submission to Chinese FDA: more exclusivity will harm patients
About I-MAK
Over 85% of Patients Diagnosed with Chronic Hepatitis C in the U.S. Are Currently NOT Receiving Treatment
The Roadmap Special Edition Report on Tenofovir Alafenamide Fumarate: April 2018
This report expands on the information provided in the original Roadmap, and most importantly, aims to provide the international community with critical analysis well in advance of when policy-makers will have to determine how TAF may be used in HIV treatment programs.
Treatment advocate tactics to expand access to antiviral therapy for HIV and viral hepatitis C in low- to high-income settings: making sure no one is left behind
Worldwide, 71 million people are infected with hepatitis C virus (HCV), which, without treatment, can lead to liver failure or hepatocellular carcinoma. HCV co-infection increases liver- and AIDS-related morbidity and mortality among HIV-positive people, despite ART. A 12-week course of HCV direct-acting antivirals (DAAs) usually cures HCV – regardless of HIV status. However, patents and…
Impact of civil society patent oppositions
Presentation by Tahir Amin at the Global Summit on Intellectual Property & Access to Medicines in the roundtable session “Challenging unmerited patents.”
The importance of patent oppositions in assisting patent examination
Presentation by Tahir Amin at the Global Summit on Intellectual Property & Access to Medicines in the parallel session “Preventing bad patents: The role of patent examination.”
Civil Society and Patent Oppositions
Presentation by Tahir Amin at the Global Summit on Intellectual Property & Access to Medicines in the plenary session “The role of civil society in the TRIPS flexibilities implementation.”